MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease Clinical Trials
4 recruiting trials for MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease. Eligibility criteria explained in plain English.
TrialFinderData lists 4 MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Naga P. Chalasani (1), University of California, San Diego (1), Post Graduate Institute of Medical Education and Research, Chandigarh (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Resmetirom (drug, 1 trial), followed by Placebo Control, LiverScope® exam.
Track MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
The purpose of this research study is to test the safety and effectiveness of the study drug, resmetirom, in participants with MASLD and HIV. This is a research study to test a...
Accurate Point of Care Liver Disease Diagnostics (Phase 2)
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a...
Cardiac Dysfunction in Patients with Fatty Liver Disease
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of...
Spleen Stiffness Measurement for the Detection of Advanced Fibrosis
Measurement of spleen stiffness (SSM) has shown potential as a complementary tool to liver stiffness measurement (LSM) for the assessment of portal hypertension in patients with...
Explore Other Conditions
Frequently Asked Questions
There are currently 4 clinical trials for MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.